RxDoctor Payments DataLook up a doctor →

Judson Davies, MD

Urology · Omaha, NENPI 1972776888

Payments from drug & device makers

$1,223,898in general payments, 2019–2025

Across 298 payments — averaging $4107.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Research & Development, LLC$1.1M
  • Johnson & Johnson$34K
  • Ferring Pharmaceuticals AS$28K
  • Janssen Scientific Affairs, LLC$13K
  • Bayer$12K
  • Ferring Pharmaceuticals Inc.$1K
  • plus $7K from 39 others

What the payments were for

  • Consulting fees$36,77655%
  • Speaking & faculty fees$16,17024%
  • Travel & lodging$5,4118%
  • Food & beverage$8,85713%
  • Education$2650%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,223,898 in reported general payments places this provider in the 95th percentile of 79 urology providers in Nebraska.

See all urology providers in Nebraska

Medicare billing

Part B allowed, 2024
$533,868
Medicare patients
784
Services billed
16,049

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide54$689,743
NubeqaDarolutamide49$533,086
XtandiEnzalutamide35$448,996
OrgovyxRelugolix66$164,318
Abiraterone Acetate131$109,785
Thiola EcTiopronin11$83,418
MyrbetriqMirabegron76$49,942
GemtesaVibegron18$17,504
Tamsulosin Hcl295$4,286
Methenamine Hippurate42$3,947
Bicalutamide31$1,948
Finasteride169$1,809
Silodosin23$1,401
Trospium Chloride26$1,127
Solifenacin Succinate50$891

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonErleada$33,844$689,74354 claims
BayerNubeqa$12,183$533,08649 claims
Astellas Pharma US IncXtandi, Myrbetriq$230$498,938111 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$147$181,82284 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$13,115$109,785131 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 79 urology providers in Nebraska.

Other urology in Omaha

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →